Liver Transplant Plenary
Nov
2026
Description
The recent increase in the global utilization of normothermic machine perfusion is changing day-to-day practice of liver transplantation, with new logistics and complexities.
Presentations
11:30 AM
- 11:45 AM
Convention Center - General Session, Hall A
QEL-001, an engineered Treg cell therapy targeting HLA-A2, demonstrates safety, phenotypic stability, durability and facilitates minimization of immunosuppression in liver transplant patients (LIBERATE)
Alberto Sanchez-Fueyo, MD PhD | Abstract Presenter
11:45 AM
- 12:00 PM
Convention Center - General Session, Hall A
Adding Normothermic Regional Perfusion Before Normothermic Machine Perfusion Enhances Early Lactate Reduction and Indirectly Reduces Early Allograft Dysfunction in DCD Liver Transplantation
ATSUSHI NISHIMAGI, MD, PhD | Abstract Presenter
12:00 PM
- 12:15 PM
Convention Center - General Session, Hall A
Waitlist Recompensation Across Steatotic Liver Disease Phenotypes: ALD, MetALD, and MASLD in 43,410 UNOS Candidates (2017–2023)
Islam B. Mohamed, MD, MSc | Abstract Presenter
12:15 PM
- 12:30 PM
Convention Center - General Session, Hall A
Extracorporeal Liver Support using a Bioengineered Liver for the Treatment of Acute Liver Failure, Alcohol Associated Hepatitis or Acute-On-Chronic Liver Failure: Results for a First-of-its-Kind Phase I Clinical Trial
Christopher Danford, MD | Abstract Presenter
